References
- Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38:971–978.
- Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord. 2004;28(Suppl 2):S14–S22.
- Pafili K, Papanas N, Maltezos E. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases? Expert Opin Investig Drugs. 2014;23:1277–1284.
- Effects of XOMA 052 on insulin production in type 1 diabetes (LATE STAGE). [cited 2016 Dec 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01788033?term=gevokizumab+type+1+diabetes&rank=1
- Study of the effects of XOMA 052 on insulin production in subjects with well controlled type 1 diabetes. [cited 2016 Dec 17]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT00998699?term=gevokizumab+type+1+diabetes&rank=2
- Sumpter KM, Adhikari S, Grishman EK, et al. Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes. Pediatr Diabetes. 2011;12:656–667.
- van Asseldonk EJ, van Poppel PC, Ballak DB, et al. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus. Clin Immunol. 2015;160:155–162.
- Moran A, Bundy B, Becker DJ, et al.; AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013;381:1905–1915.
- Seelig E, Timper K, Falconnier C, et al. Interleukin-1 antagonism in type 1 diabetes of long duration. Diabetes Metab. 2016;42:453–456.
- Janzen KM, Steuber TD, Nisly SA. GLP-1 agonists in type 1 diabetes mellitus. Ann Pharmacother. 2016;50:656–665.
- Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39:1702–1710.
- Ahrén B, Hirsch IB, Pieber TR, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016;39:1693–1701.
- Guo H, Fang C, Huang Y, et al. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;121:184–191.
- Pafili K, Maltezos E, Papanas N. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. Expert Opin Investig Drugs. 2016;25:1133–1152.
- Pafili K, Papanas N. Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: no enemy but time? Expert Opin Pharmacother. 2015;16:453–456.
- Comee M, Peters A. The changing therapeutic armamentarium for patients with type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2016;23:106–110.
- Lane W. SGLT-2 inhibitors as adjunct therapy in type 1 diabetes: reason for hope and caution. Endocr Pract. 2016;22:371–373.
- Isaji M. SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl. 2011;79:S14–S19.
- Haas B, Eckstein N, Pfeifer V, et al. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes. 2014;4:e143.
- Background document. Dapagliflozin. Bms-512148. NDA 202293. US food& drug administration (FDA). Endocrinologic & metabolic drug advisory committee (EMDAC). [cited 2015 Dec 18]. Available from: http://www.fda.gov/downloads/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm378079.pdf
- Liakos A, Karagiannis T, Bekiari E, et al. Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2015;6:61–67.
- Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(20):405–415.
- Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124–136.
- Launch of Suglat® tablets, a selective SGLT2 inhibitor for treatment of type 2 diabetes, first SGLT2 inhibitor in Japan, providing new options in the treatment of type 2 diabetes. [cited 2016 Dec 27]. Available from: http://www.astellas.com/en/corporate/news/detail/launch-of-suglat-tablets-a-sel.html
- Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66:975–987.
- Pharmacodynamics, pharmacokinetics, and safety of ASP1941 in patients with type 1 diabetes mellitus. [cited 2016 Dec 17]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02529449?term=ipragliflozin+type+1+diabetes&rank=2
- A study of ASP1941 in combination with insulin in patients with type 1 diabetes mellitus. [cited 2016 Dec 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT02897219?term=ipragliflozin+type+1+diabetes&rank=1
- Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care. 2012;35:2198–2200.
- Mikhail N. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. Expert Opin Investig Drugs. 2015;24:1381–1387.
- JARDIANCE® (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014. [cited 2016 Dec 27]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
- Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014;23:875–882.
- Perkins BA, Cherney DZ, Soleymanlou N, et al. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes. Plos One. 2015;10:e0141085.
- Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480–1483.
- Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–597.
- Empagliflozin add-on to insulin in type 1 diabetes mellitus over 28 days. [cited 2016 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01969747?term=empagliflozin+type+1+diabetes&rank=3§=X1437056#base
- Empagliflozin as adjunctive to insulin therapy over 26 weeks in patients with T1DM (EASE-3). [cited 2016 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02580591?term=NCT02580591&rank=1
- Empagliflozin as adjunctive to inSulin thErapy in type 1 diabetes over 52 weeks (EASE-2). [cited 2016 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02414958?term=empagliflozin+type+1+diabetes&rank=4
- Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2013;65:317–327.
- Lapuerta P, Zambrowicz B, Strumph P, et al. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res. 2015;12:101–110.
- Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38:1181–1188.
- Efficacy, safety, and tolerability study of sotagliflozin as adjunct therapy in adult patients with type 1 diabetes mellitus who have inadequate glycemic control with insulin therapy (inTandem1). [cited 2017 Jan 02]. Available from: https://clinicaltrials.gov/ct2/show/NCT02384941?term=sotagliflozin+and+type+1+diabetes&rank=1
- Efficacy, safety, and tolerability study of sotagliflozin as adjunct therapy in adult patients with type 1 diabetes mellitus who have inadequate glycemic control with insulin therapy (inTandem2). [cited 2017 Jan 02]. Available from: https://clinicaltrials.gov/ct2/show/NCT02421510?term=sotagliflozin+and+type+1+diabetes&rank=2
- A phase 3 study to evaluate the safety of sotagliflozin in patients with type 1 diabetes who have inadequate glycemic control with insulin therapy alone (inTandem3). [cited 2017 Jan 02]. Available from: https://clinicaltrials.gov/ct2/show/NCT02531035?term=sotagliflozin+and+type+1+diabetes&rank=4
- Henry RR, Thakkar P, Tong C, et al. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38:2258–2265.
- Rodbard HW, Peters AL, Slee A, et al. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care. 2017;40:171–180.
- Peters AL, Henry RR, Thakkar P, et al. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016;39:532–538.
- Gao HX, Regier EE, Close KL. European Association for the study of diabetes 51st Annual Meeting. J Diabetes. 2016;8:177–180.
- Harati H, Sharma V, Motazedi A. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: report of two cases with hyperglycemic ketoacidosis in type 1 diabetes. J Diabetes. 2016;8:165.
- Pafili K, Maltezos E, Papanas N. Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2016;8:1–14.
- Pafili K, Papanas N. Tofogliflozin: the road goes ever on. Expert Opin Pharmacother. 2014;15:1197–1201.
- Dapagliflozin. Summary of product characteristics. [cited 2017 Feb 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf
- Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:357–365.
- Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38:405–414.
- Whaley JM, Tirmenstein M, Reilly TP, et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2012;5:135–148.
- Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223–2233.
- Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520–526.
- Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513–519.
- Macdonald FR, Peel JE, Jones HB, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab. 2010;12:1004–1012.
- Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16:137–144.
- Merovci A, Abdul-Ghani M, Mari A, et al. Effect of dapagliflozin with and without acipimox on insulin sensitivity and insulin secretion in T2DM males. J Clin Endocrinol Metab. 2016;101:1249–1256.
- Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab. 2015;100:1927–1932.
- Salsali A, Bastien A, Mansfield T, et al. Dapagliflozin improves hyperglycemia and β‐cell function without increasing hypoglycemic episodes in patients with type 2 diabetes mellitus. American Association of Clinical Endocrinologists (AACE), San Diego, CA, April 13–17, 2011. Abstract 204
- Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
- Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412–419.
- BMS - safety, pharmacokinetics (PK) and pharmacodynamics (PD) of dapagliflozin in type 1 diabetes. [cited 2017 Mar 05]. Available from: https://clinicaltrials.gov/ct2/show/NCT01498185?term=dapagliflozin+type+1+diabetes+mellitus&rank=4
- Phase 1 study to explore the safety and pharmacokinetics of DAPAglifozin in adolescents and adults with type 1 diabetes (DAPA-IIT1). [cited 2017 Mar 05]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02325206?term=dapagliflozin+type+1+diabetes+mellitus&rank=11
- The PK and PD of dapagliflozin therapy in combination with insulin in Japanese subjects with T1DM. [cited 2017 Mar 05]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02582840?term=dapagliflozin+type+1+diabetes+mellitus&rank=6
- Tang W, Leil TA, Johnsson E, et al. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18:236–240.
- Hatanaka T, Ogawa D, Tachibana H, et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect. 2016;4:e00239.
- Tamez HE, Tamez AL, Garza LA, et al. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 2015;14:78.
- Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab. 2016;101:3506–3515.
- Dapagliflozin plus liraglutide and insulin effective in T1D. But came with high risk of ketoacidosis, finds small study. [cited 2017 Mar 06]. Available from: http://www.medpagetoday.com/meetingcoverage/aace/58176
- Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. [cited 2017 Mar 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02518945?term=dapagliflozin+type+1+diabetes+mellitus&rank=5
- The safety and efficacy of dapagliflozin therapy in combination with insulin in Japanese subjects with Type 1 Diabetes Mellitus (T1DM). [cited 2017 Mar 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02582814?term=dapagliflozin+type+1+diabetes+mellitus&rank=1
- Dapagliflozin evaluation in patients with inadequately controlled type 1 diabetes (DEPICT 1). [cited 2017 Mar 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02268214?term=dapagliflozin+type+1+diabetes+mellitus&rank=2
- Dapagliflozin evaluation in patients with inadequately controlled type 1 diabetes (DEPICT 2). [cited 2017 Mar 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02460978?term=dapagliflozin+type+1+diabetes+mellitus&rank=3
- Dapagliflozin in type 1 diabetes (DapaT1DM). [cited 2017 Mar 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02211742?term=dapagliflozin+type+1+diabetes+mellitus&rank=10
- Henry RR, Dandona P, Pettus J, et al. Dapagliflozin in patients with type 1 diabetes: a post-hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels from a phase IIa pilot study. Diabetes Obes Metab. 2017 Jan 18. 19: 814–821. [Epub ahead of print].
- Effects of single doses of liraglutide and dapagliflozin on hyperglycemia and ketogenesis in type 1 diabetes (1974). [cited 2017 Mar 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02777073?term=dapagliflozin+type+1+diabetes+mellitus&rank=7
- An investigation into the effect of dapagliflozin on ketogenesis in type 1 diabetes. [cited 2017 Mar 06]. Available from: https://clinicaltrials.gov/ct2/show/NCT02962492?term=dapagliflozin+type+1+diabetes+mellitus&rank=9
- Papanas N, Demetriou M, Maltezos E. A fairy tale of modern insulin therapy in type 1 diabetes. World J Diabetes. 2010;1:109–110.
- Papatheodorou K, Banach M, Edmonds M, et al. Complications of diabetes. J Diabetes Res. 2015;2015:189525.
- Pafili K, Papanas N, Maltezos E. Treatment of diabetic complications: how can we learn by seeking and blundering? Angiology. 2015;66:301–303.
- Chamberlain JJ, Rhinehart AS, Shaefer CF Jr, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care In Diabetes. Ann Intern Med. 2016;164:542–552.
- Chillarón JJ, Benaiges D, Mañé L, et al. Obesity and type 1 diabetes mellitus management. Minerva Endocrinol. 2015;40:53–60.
- Harris KB, Boland CL. Adjunctive role of glucagon-like peptide-1 receptor agonists in the management of type 1 diabetes mellitus. Pharmacotherapy. 2016;36:1011–1020.
- Popovic DS, Stokic E, Popovic SL. GLP-1 receptor agonists and type 1 diabetes - where do we stand? Curr Pharm Des. 2015;21:5292–5298.
- Crisci I, Aragona M, Politi KS, et al. GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach. Acta Diabetol. 2015;52:1129–1133.
- Unger J. Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes. Curr Diab Rep. 2013;13:663–668.
- Lima-Martínez MM, Guerra-Alcalá E, Contreras M, et al. One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin. Endocrinol Diabetes Metab Case Rep. 2014;140072.
- Pinheiro MM, Pinheiro FM, Torres MA. Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Endocrinol Diabetes Metab Case Rep. 2016;2016:pii: 16-0099.
- Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud. 2016;13:217–225.
- Adachi J, Inaba Y, Maki C. Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin. Intern Med. 2017;56:187–190.
- Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017 Jan 18. e2886. [Epub ahead of print]
- Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
- Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
- Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–270.
- Kalra S, Gupta Y, Patil S. Sodium-glucose cotransporter-2 inhibition and the insulin: glucagon ratio: unexplored dimensions. Indian J Endocrinol Metab. 2015;19:426–429.
- Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–1693.
- Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37:187–194.
- Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642.
- Klocker AA, Phelan H, Twigg SM, et al. Blood β-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in type 1 diabetes: a systematic review. Diabet Med. 2013;30:818–824.
- Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell-centric classification schema. Diabetes Care. 2016;39:179–186.
- Fourlanos S, Perry C, Stein MS, et al. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care. 2006;29:970–975.
- Newman JC, Verdin E. Beta-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Pract. 2014;106:173–181.
- Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15:412–426.
- Greene AE, Todorova MT, Seyfried TN. Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. J Neurochem. 2003;86:529–537.
- Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003;112:892–901.
- Reger MA, Henderson ST, Hale C, et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004;25:311–314.
- Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “Thrifty Substrate” hypothesis. Diabetes Care. 2016;39:1108–1114.
- Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
- Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
- EMA: amputation warning with SGLT2 inhibitors must be on label. [cited 2017 Mar 11]. Available from: http://www.medscape.com/viewarticle/875649?src=wnl_tp10n_170310_mscpedit_ous&uac=195276AT&impID=1304800
- CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS). [cited 2017 Mar 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01032629
- A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus (CANVAS-R. [cited 2017 Mar 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01989754